Holen Sie sich die Stockscreener-App
13.88
0.07%
0.01
Handel nachbörslich:
13.85
-0.03
-0.22%
Schlusskurs vom Vortag:
$13.87
Offen:
$14
24-Stunden-Volumen:
1.23M
Relative Volume:
0.66
Marktkapitalisierung:
$2.22B
Einnahmen:
$276.98M
Nettoeinkommen (Verlust:
$-59.46M
KGV:
-34.81
EPS:
-0.3987
Netto-Cashflow:
$-48.95M
1W Leistung:
+8.18%
1M Leistung:
-2.25%
6M Leistung:
-25.42%
1J Leistung:
+57.01%
1-Tages-Spanne:
$13.73
$14.27
1-Wochen-Bereich:
$12.50
$14.27
52-Wochen-Spanne:
$8.50
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
13.88 | 2.22B | 276.98M | -59.46M | -48.95M | -0.3987 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
ADPT SEC FilingsAdaptive Biotechnologies 10-K, 10-Q, 8-K Forms - Stock Titan
Hear Adaptive Biotechnologies' June 3 investor talk live online - Stock Titan
Adaptive Biotechnologies CFO Kyle Piskel sells $40,619 in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CFO Kyle Piskel sells $40,619 in stock - Investing.com
Adaptive Biotechnologies (ADPT) CFO tax-related share sale leaves 256,725 shares held - Stock Titan
UBS Group AG Purchases 257,947 Shares of Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Proposed sale of 3,160 RSUs by ADPT (NASDAQ: ADPT) reported - Stock Titan
Viking firms hold 18.8% of Adaptive Biotechnologies (NASDAQ: ADPT) - Stock Titan
ADPT Stock Price, Quote & Chart | ADAPTIVE BIOTECHNOLOGIES (NASDAQ:ADPT) - ChartMill
ADPT Maintained by Morgan Stanley -- Price Target Lowered to $18 - GuruFocus
Morgan Stanley Cuts Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $18.00 - MarketBeat
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong MRD Growth And Raised Full Year Guidance - Yahoo Finance
Analysts Expect Breakeven For Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Before Long - Moomoo
How Strong MRD Growth and Upgraded 2026 Guidance Will Impact Adaptive Biotechnologies (ADPT) Investors - simplywall.st
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2026 Earnings Call Transcript - Insider Monkey
Adaptive Biotech Q1 2026 slides: MRD revenue surges 53%, guidance raised - Investing.com Australia
JPMorgan Chase & Co. Lowers Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $19.00 - MarketBeat
Adaptive Biotechnologies Corporation 10-Q Report 2026: Financial Statements, Risk Factors, and Forward-Looking Statements 173031 - Minichart
Adaptive Biotech Q1 2026 slides: MRD revenue surges 53%, guidance raised By Investing.com - Investing.com South Africa
Earnings call transcript: Adaptive Biotechnologies Q1 2026 revenue beats forecast By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Adaptive Biotechnologies Q1 2026 revenue beats forecast - Investing.com
Transcript: Adaptive Biotechnologies Q1 2026 Earnings Conference Call - Benzinga
Adaptive Biotechnologies: Q1 Earnings Snapshot - marketscreener.com
Adaptive Biotechnologies Corp reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] Adaptive Biotechnologies Corp Quarterly Earnings Report - Stock Titan
Q1 2026 Adaptive Biotechnologies Corp Earnings Call Transcript - GuruFocus
MSN Money - MSN
Adaptive Biotechnologies (NASDAQ: ADPT) lifts 2026 MRD outlook after 35% Q1 revenue growth - Stock Titan
Adaptive lifts 2026 MRD outlook after $70.9M quarter, 41% test gain - Stock Titan
Adaptive Biotechnologies earnings on deck after 55% revenue surge By Investing.com - Investing.com South Africa
Adaptive Biotechnologies earnings on deck after 55% revenue surge - Investing.com
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. - Yahoo Finance
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. - The Motley Fool
Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares - Investing.com
How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street Assumptions - Yahoo Finance
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):